Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cytochrome P450, family 19, subfamily A, polypeptide 1 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma cruzi | cytochrome P450, putative | cytochrome P450, family 19, subfamily A, polypeptide 1 | 503 aa | 425 aa | 18.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | glucose-6-phosphate isomerase, putative | 0.0049 | 0.2043 | 1 |
Mycobacterium tuberculosis | Probable 6-phosphogluconolactonase DevB (6PGL) | 0.009 | 0.5947 | 1 |
Echinococcus granulosus | 6 phosphogluconolactonase | 0.0128 | 0.9435 | 1 |
Chlamydia trachomatis | 6-phosphogluconolactonase | 0.0128 | 0.9435 | 1 |
Mycobacterium leprae | Probable 6-phosphogluconolactonase DevB (6PGL) | 0.0128 | 0.9435 | 1 |
Trichomonas vaginalis | glucose-6-phosphate isomerase, putative | 0.0049 | 0.2043 | 1 |
Leishmania major | glucose-6-phosphate isomerase | 0.0049 | 0.2043 | 0.1317 |
Trypanosoma brucei | 6-phosphogluconolactonase | 0.0128 | 0.9435 | 1 |
Trypanosoma cruzi | glucose-6-phosphate isomerase, glycosomal, putative | 0.0049 | 0.2043 | 0.1317 |
Giardia lamblia | Glucose-6-phosphate isomerase | 0.0049 | 0.2043 | 1 |
Loa Loa (eye worm) | phosphoglucose isomerase | 0.0049 | 0.2043 | 0.2043 |
Trichomonas vaginalis | glucose-6-phosphate isomerase, putative | 0.0049 | 0.2043 | 1 |
Mycobacterium ulcerans | 6-phosphogluconolactonase | 0.0128 | 0.9435 | 1 |
Schistosoma mansoni | NAALADASE L peptidase (M28 family) | 0.0085 | 0.5473 | 0.5346 |
Trypanosoma brucei | glucose-6-phosphate isomerase, glycosomal | 0.0049 | 0.2043 | 0.1317 |
Echinococcus multilocularis | n acetylated alpha linked acidic dipeptidase 2 | 0.013 | 0.9701 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0122 | 0.8884 | 0.8884 |
Brugia malayi | 6-phosphogluconolactonase family protein | 0.0128 | 0.9435 | 1 |
Echinococcus multilocularis | 6 phosphogluconolactonase | 0.0128 | 0.9435 | 0.9653 |
Trypanosoma cruzi | 6-phosphogluconolactonase, putative | 0.0128 | 0.9435 | 1 |
Plasmodium vivax | glucose-6-phosphate isomerase, putative | 0.0049 | 0.2043 | 1 |
Treponema pallidum | glucose-6-phosphate 1-dehydrogenase | 0.0128 | 0.9435 | 1 |
Trypanosoma cruzi | glucose-6-phosphate isomerase, glycosomal, putative | 0.0049 | 0.2043 | 0.1317 |
Schistosoma mansoni | 6-phosphogluconolactonase | 0.0128 | 0.9435 | 1 |
Plasmodium falciparum | glucose-6-phosphate isomerase | 0.0049 | 0.2043 | 1 |
Schistosoma mansoni | glucose-6-phosphate isomerase | 0.0049 | 0.2043 | 0.1317 |
Loa Loa (eye worm) | 6-phosphogluconolactonase | 0.0128 | 0.9435 | 0.9435 |
Trypanosoma cruzi | 6-phosphogluconolactonase, putative | 0.0128 | 0.9435 | 1 |
Leishmania major | 6-phosphogluconolactonase | 0.0128 | 0.9435 | 1 |
Schistosoma mansoni | 6-phosphogluconolactonase | 0.0128 | 0.9435 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0089 | 0.5772 | 0.5772 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.2043 | 0.2043 |
Toxoplasma gondii | glucose-6-phosphate isomerase GPI | 0.0049 | 0.2043 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | = 0.063 uM | Inhibition of binding to human Placental Cytochrome P450 19A1 | ChEMBL. | 2033599 |
Ki (binding) | = 0.063 uM | Inhibition of binding to human Placental Cytochrome P450 19A1 | ChEMBL. | 2033599 |
Ratio (binding) | = 50700 | Ratio of Kcat to Ki for human placental cytochrome P450 19A1 | ChEMBL. | 2033599 |
Ratio (binding) | = 50700 | Ratio of Kcat to Ki for human placental cytochrome P450 19A1 | ChEMBL. | 2033599 |
T50 (ADMET) | = 3.6 min | Pseudo first-order inactivation rate of the compound calculated by using Kitz-Wilson Plot | ChEMBL. | 2033599 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.